14,797
edits
Helminthic therapy and COVID-19: Difference between revisions
m
→The emerging science: Added a citation.
m (→The emerging science: Added citation.) |
m (→The emerging science: Added a citation.) |
||
| Line 16: | Line 16: | ||
== The emerging science == | == The emerging science == | ||
* 2023 May [https://pubmed.ncbi.nlm.nih.gov/37038955/ Immunological interactions in helminths-SARS CoV-2 coinfection: Could old enemy be a friend today?] | |||
:{{Quote|indent}}… COVID-19 severity in patients with chronic helminth infections (CHIs) is mild, as immuno-suppressive anti-inflammatory cytokines counterbalance the risk of cytokine storm. Here, an overview of the interplay between helminths and COVID-19 severity is given.{{Quote|/indent}} | |||
* 2023 Feb 9 [https://pubmed.ncbi.nlm.nih.gov/36785786/ COVID-19 morbidity in lower versus higher income populations underscores the need to restore lost biodiversity of eukaryotic symbionts] | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908430/pdf/main.pdf PDF] | * 2023 Feb 9 [https://pubmed.ncbi.nlm.nih.gov/36785786/ COVID-19 morbidity in lower versus higher income populations underscores the need to restore lost biodiversity of eukaryotic symbionts] | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908430/pdf/main.pdf PDF] | ||